Stereotactic Body Radiation Therapy for Post-chemoradiation Residual Disease in Stage II/III Non-small Cell Lung Cancer
Lung cancer represents one of the most challenging malignancies to manage. Cure rates have
only marginally improved in the last 20 years. It is the most commonly fatal cancer in both
men and women with overall 5 year survivals of 15%. Lung cancer kills more Americans than
the next three most common malignancies combined.
Most non small cell lung cancer (NSCLC) presents at advanced stages. Only approximately 25%
present with stage I/II disease, 40% with stage III and 35% patients present with stage IV.
(1) The optimal treatment of stage II/III NSCLC is complex. For those patients who are
surgical candidates and a complete resection is technically feasible, radical surgery
remains the standard of care. Traditionally, those patients with multiple N2 nodal levels or
T4 disease are considered inoperable. Given that the average age of patients diagnosed with
NSCLC is in their mid-60's and usually have long smoking histories, many patients are
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the toxicity of the SBRT boost dose by estimating the proportion of subjects enrolled who develop pneumonitis
30 days post SBRT
Ronald C. McGarry, MD, PhD.
University of Kentucky
United States: Institutional Review Board
|Markey Cancer Center||Lexington, Kentucky 40536|